Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Rapid Therapeutic Science Laboratories, Inc. (RTSL) Operating Expenses (2016 - 2023)

Rapid Therapeutic Science Laboratories' Operating Expenses history spans 8 years, with the latest figure at $103732.0 for Q2 2023.

  • For Q2 2023, Operating Expenses fell 19.2% year-over-year to $103732.0; the TTM value through Jun 2023 reached $547591.0, down 73.17%, while the annual FY2022 figure was $1.3 million, 41.95% down from the prior year.
  • Operating Expenses for Q2 2023 was $103732.0 at Rapid Therapeutic Science Laboratories, up from $98294.0 in the prior quarter.
  • Across five years, Operating Expenses topped out at $789393.0 in Q1 2022 and bottomed at -$27342.0 in Q4 2022.
  • The 5-year median for Operating Expenses is $249240.0 (2020), against an average of $315952.1.
  • The largest annual shift saw Operating Expenses skyrocketed 2868.44% in 2020 before it crashed 104.36% in 2022.
  • A 5-year view of Operating Expenses shows it stood at $141867.0 in 2019, then skyrocketed by 337.44% to $620582.0 in 2020, then grew by 1.08% to $627300.0 in 2021, then crashed by 104.36% to -$27342.0 in 2022, then soared by 479.39% to $103732.0 in 2023.
  • Per Business Quant, the three most recent readings for RTSL's Operating Expenses are $103732.0 (Q2 2023), $98294.0 (Q1 2023), and -$27342.0 (Q4 2022).